Page 181 - Read Online

Ravegnini et al. Cancer Drug Resist 2019;2:107-15 I http://dx.doi.org/10.20517/cdr.2019.02 Page 113

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Mei L, Du W, Idowu M, von Mehren M, Boikos SA. Advances and challenges on management of gastrointestinal stromal tumors. Front
Oncol 2018;8:135.
2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
3. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal
tumors. Science 1998;279:577-80.
4. Ravegnini G, Sammarini G, Angelini S, Hrelia P. Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and
chronic myeloid leukemia. Expert Opin Drug Metab Toxicol 2016;12:733-42.
5. Ricci R, Dei Tos AP, Rindi G. GISTogram: a graphic presentation of the growing GIST complexity. Virchows Arch 2013;463:481-7.
6. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Gastroenterol Clin North Am 2013;42:39.
7. Nannini M, Urbini M, Astolfi A, Biasco G, Pantaleo MA. The progressive fragmentation of the KIT/PDGFRA wild-type (WT)
gastrointestinal stromal tumors (GIST). J Transl Med 2017;15:113.
8. Mei L, Smith SC, Faber AC, Trent J, Grossman SR, et al. Gastrointestinal stromal tumors: the GIST of precision medicine. Trends
Cancer 2018;4:74-91.
9. Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal
stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic. JAMA Oncol 2016;2:922-8.
10. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011;11:865-78.
11. Indio V, Astolfi A, Tarantino G, Urbini M, Patterson J, et al. Integrated molecular characterization of gastrointestinal stromal tumors
(GIST) harboring the rare D842V mutation in PDGFRA gene. Int J Mol Sci 2018;19:732.
12. Angelini S, Ravegnini G, Fletcher JA, Maffei F, Hrelia P. Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor
treatment in the era of personalized therapy. Pharmacogenomics 2013;14:941-56.
13. de Melo Maia B, Lavorato-Rocha AM, Rodrigues IS, Baiocchi G, Cestari FM, et al. Prognostic significance of c-KIT in vulvar cancer:
bringing this molecular marker from bench to bedside. J Transl Med 2012;10:150.
14. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha
gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-7.
15. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, et al. PDGFRA activating mutations in gastrointestinal stromal tumors.
Science 2003;299:708-10.
16. Huss S, Elges S, Trautmann M, Sperveslage J, Hartmann W, et al. Classification of KIT/PDGFRA wild-type gastrointestinal stromal
tumors: implications for therapy. Expert Rev Anticancer Ther 2015;15:623-8.
17. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with
allelic loss on chromosome 9. Oncogene 2003;22:9217-24.
18. Scherer D, Rachakonda PS, Angelini S, Mehnert F, Sucker A, et al. Association between the germline MC1R variants and somatic
BRAF/NRAS mutations in melanoma tumors. J Invest Dermatol 2010;130:2844-8.
19. Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies
for actionable mutations. Oncogene 2018;37:3183-99.
20. Ravegnini G, Quero G, Sammarini G, Giustiniani MC, Castri F, et al. Gastrointestinal juvenile-like (inflammatory/hyperplastic) mucosal
polyps in neurofibromatosis type 1 with no concurrent genetic or clinical evidence of other syndromes. Virchows Arch 2019;474:259-64.
21. Urbini M, Astolfi A, Indio V, Heinrich MC, Corless CL, et al. SDHC methylation in gastrointestinal stromal tumors (GIST): a case
report. BMC Med Genet 2015;16:87.
22. Miettinen M, Lasota J. Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. Int J Biochem Cell Biol
2014;53:514-9.
23. Pantaleo MA, Astolfi A, Urbini M, Nannini M, Paterini P, et al. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate
dehydrogenase complex in KIT/PDGFRA wild-type GIST. Eur J Hum Genet 2014;22:32-9.
24. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Supplement_4):iv68-78.